In Vivo Gene Editing Partnerships

ARCUS HDR Gene Insertion and Gene Excision Validated by Big Pharma and Biotech Partners



  • Potential first ARCUS gene insertion program to reach clinic for OTC Deficiency affecting pediatric population
  • Longest-running study of in vivo gene editing in primates demonstrates safety and stability of ARCUS-mediated editing1


  • Equity stake in iECURE
  • Milestone payments and royalties on sales


  • Novel approach to bring sophisticated edits beyond the liver
    • — Gene insertion in hematopoietic stem cells in vivo


  • $75M Upfront Payments
  • $1.4B Potential Milestone Payments
  • Mid-single-digit to low double-digit royalties

Ex Vivo CAR T Partnerships Enable Funding Gene Editing Platform

Precision eligible to receive up to $47M in upfront & near-term payments with >$900M in potential milestone payments


Exclusive global license to azer-cel 
 for cancer indications


  • $29M Upfront & Potential Near-term Payments
  • $198M Potential Milestone Payments
  • Option to nominate up to three research programs, each with $145M potential milestone payments and tiered royalties on net sales
  • Double-Digit Royalties on Net Sales


Exclusive global license to azer-cel for non-cancer indications, including autoimmune diseases


  • $17.5M Upfront & Potential Near-term Payments
    • — Mix of cash and equity with any equity purchased at 100% premium to 30-day VWAP
  • $288M Potential Milestone Payments
  • High-Single-Digit to Low-Double-Digit Royalties on Net Sales

Partnering is a cornerstone of our company’s growth and success.
Through these collaborations, we deepen our capabilities with new tools, new resources, and new expertise.

Partner with Us
Novartis Logo

Exclusive in vivo gene editing research and development collaboration and license agreement with Novartis to develop a single ARCUS nuclease designed as a potential single-administration treatment for hemoglobinopathies including sickle cell disease and beta thalassemia.

Learn more about this partnership ›


License and collaboration agreement with iECURE to advance Precision’s PBGENE-PCSK9 candidate into Phase 1 studies and gain access to PCSK9-directed ARCUS nuclease to develop additional gene editing therapies.

Learn more about this partnership ›

Research, collaboration, and license agreement with the University of Pennsylvania to collaborate on the preclinical development for gene editing products involving the delivery of an ARCUS nuclease.

Learn more about this partnership ›

Acuitas Logo

Option agreement to evaluate Acuitas Therapeutic Inc.’s lipid nanoparticle (LNP) technology for delivery of ARCUS with rights to license, develop, and commercialize LNP-delivered ARCUS products.

Learn more about Acuitas ›

Global rights to azer-cel, allogeneic CAR T candidate for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future.

Learn more about Imugene ›